Loading...
Please wait, while we are loading the content...
Similar Documents
Targeting Hepcidin to Treat Anemia of Chronic Kidney Disease
| Content Provider | Semantic Scholar |
|---|---|
| Author | Panwar, Bhupesh |
| Copyright Year | 2016 |
| Abstract | Anemia is a common complication of Chronic Kidney Disease (CKD) [1]. Traditionally, the use of Erythropoiesis Stimulating Agents (ESAs), iron infusions and blood transfusions are considered to be the cornerstone therapeutics for the treatment of anemia of CKD. However, these treatment options are not only costly and invasive, use of ESAs has been recently linked to adverse events and poor outcomes in several large scale randomized clinical trials in the CKD population [2-4]. This has recently shifted the focus on finding newer therapeutics that are safer, cost effective and efficacious. Over the last decade, the research in this direction has gained momentum due to the discovery of hepcidin, a novel 25 amino-acid peptide, which is now believed to be the master regulator of iron homeostasis in health and disease [5]. |
| Starting Page | 1 |
| Ending Page | 2 |
| Page Count | 2 |
| File Format | PDF HTM / HTML |
| DOI | 10.36876/smjnt.1001 |
| Volume Number | 1 |
| Alternate Webpage(s) | https://www.jsmcentral.org/sm-nephrology-therapeutics/fulltext_smjnt-v1-1001.pdf |
| Alternate Webpage(s) | https://doi.org/10.36876/smjnt.1001 |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
